injectable products during scale-up stages.

3. Responsibilities

• Formulation Scientist: Designs and monitors the scale-up trials.
• Manufacturing Team: Executes the scale-up batches under supervision.
• QA: Reviews the scale-up protocols and reports for compliance.

4. Accountability

Head – Formulation Development and Head – QA are accountable for ensuring proper documentation and evaluation of the scale-up studies.

5. Procedure

5.1 Pre-Scale-Up Assessment

1. Review lab-scale batch records and performance data.
2. Confirm availability of equipment that simulates production scale operations (mixers, filters, filling systems, etc.).
3. Define critical quality attributes (CQAs) and critical process parameters (CPPs).

5.2 Batch Size Selection

• Typically, 1/10th or 1/3rd of the commercial batch size may be selected for initial scale-up trials.
• Final scale-up batch shall match commercial batch size for process validation.

5.3 Equipment Qualification

1. Ensure that all equipment to be used for scale-up is qualified (IQ, OQ, PQ completed).
2. Log equipment ID and calibration status in the scale-up protocol.

5.4 Execution of Scale-Up Batch

1. Follow scale-up protocol approved by QA and Technical Head.
2. Capture detailed observations during each manufacturing step including solution preparation, filtration, filling, and sealing.
3. Record yield, batch time, equipment load capacities, and environmental monitoring parameters.

5.5 In-Process and Finished Product Testing

• Conduct pH, osmolality, assay, impurity, particulate matter, and sterility testing.
• Compare with lab-scale data for consistency.

5.6 Risk Identification and Troubleshooting

1. Identify scale-dependent variables (e.g., mixing time, heat transfer, hold time).
2. Modify process parameters and document rationale in the deviation report if applicable.

5.7 Documentation

• Prepare a comprehensive Scale-Up Batch Report (Annexure-1).
• Log all deviations, observations, and critical parameter shifts.
• Include batch manufacturing records, in-process data, and analytical reports.

6. Abbreviations

• CQA: Critical Quality Attribute
• CPP: Critical Process Parameter
• IQ/OQ/PQ: Installation/Operational/Performance Qualification

7. Documents

1. Scale-Up Batch Report – Annexure-1
2. Batch Manufacturing Record – Annexure-2
3. In-Process Test Results – Annexure-3

8. References

• ICH Q8 (R2) – Pharmaceutical Development
• FDA Guidance for Industry – Process Validation: General Principles and Practices

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Executive	Head QA
Department	Product Development	Quality Assurance	Quality Assurance

11. Annexures

Annexure-1: Scale-Up Batch Report

Details of batch size, process parameters, deviations, yields, in-process and finished product test results.

Annexure-2: Batch Manufacturing Record

Step-by-step instructions with fields for operator signatures, date, time, and equipment usage.

Annexure-3: In-Process Test Results

Compiled data for pH, osmolality, assay, impurities, sterility, and particulate matter.

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
20/05/2022	1.0	Initial SOP	Formulation to plant scale transition	Head QA
18/06/2025	2.0	Enhanced with risk-based elements	Process improvements	Head QA